Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.